Skip to main content

MGC Pharmaceuticals' focus "will not change" despite psilocybin news

MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) chief commercial officer Robert Clements speaks to Proactive after announcing that the company has been granted permission by the Slovenian government to conduct research into psilocybin, a naturally occurring psychedelic compound found in certain types of mushrooms.

The company will work in partnership with other pharmaceutical companies to determine the best potential use for psilocybin.

Clements says that "the focus of MGC will not change" despite the news, adding that it is fully committed to its current pipeline of products.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  244.22
+21.36 (9.58%)
AAPL  270.37
-1.03 (-0.38%)
AMD  256.12
+1.28 (0.50%)
BAC  53.45
+0.42 (0.79%)
GOOG  281.82
-0.08 (-0.03%)
META  648.35
-18.12 (-2.72%)
MSFT  517.81
-7.95 (-1.51%)
NVDA  202.49
-0.40 (-0.20%)
ORCL  262.61
+5.72 (2.23%)
TSLA  456.56
+16.46 (3.74%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.